About
Aims and scope
BMJ Open Respiratory Research is a peer-reviewed, open access journal publishing respiratory and critical care medicine. It is the sister journal to Thorax and co-owned by the British Thoracic Society and BMJ. The journal focuses on robustness of methodology and scientific rigour with less emphasis on novelty or perceived impact.
BMJ Open Respiratory Research operates a rapid review process, with continuous publication online, ensuring timely, up-to-date research is available worldwide.
The journal publishes review articles and all research study types:
- Basic science including laboratory based experiments and animal models
- Pilot studies or proof of concept
- Observational studies
- Study protocols
- Registries
- Clinical trials from phase I to multicentre randomised clinical trials
- Systematic reviews and meta-analyses
Editorial Board
For information about the BMJ Open Respiratory Research Editors-in-Chief Professor Stephen Chapman and Dr Matt Wise and their editorial team, please refer to the Editorial Board page
Ownership
BMJ Open Respiratory Research is co-owned by the British Thoracic Society and BMJ.
Journal information
| Publication Model | Open access |
|---|---|
| Frequency | Continuous |
| Launch date | 2013 |
| Digital Archive | LOCKSS |
| Indexed by | PubMed Central, Scopus, Google Scholar |
| Citescore | 0.36 (2016) |
| Peer Review Model | Single blind; the names of reviewers are hidden from the author |
| ISSN (online) | 2052-4439 |
Journal statistics
| Acceptance Rate | 80% |
|---|---|
| Instant Rejection Rate | 16% |
| Time to Submission to First Decision | 34 days |
| Time to Acceptance to Publication | 17 days |
Contact information
For all contact information please refer to the Contact Us page.
For authors
Please refer to the Instructions for Authors.
For reviewers
Please refer to the Instructions for Reviewers.
To advertise
Rights and permissions
Affiliations
BMJ Open Respiratory Research is an official journal of the British Thoracic Society.
BMJ is a founding organisation of the AllTrials initiative, which calls for all past and present clinical trials to be registered and their results reported.